Abstract
The development of anefficacious vaccine against the human immuno deficiency virus (HIV) is of great urgency, because it is accepted that vaccination is the only means capable of controlling the AIDS pandemic. The foundation of HIV vaccine development is the analysis of immune responses during natural infection and the utilization of this knowledge for the development of protective immunization strategies. Initial vaccine development and experimentation are usually in animal models, including murine, feline, and nonhuman primates. Experimental vaccine can didates are closely studies for both efficacy and safety before proceeding to human clinical trials. There are anumber of different therapeutic and prophylactice vaccine strategies currently being studied in human clinical trials. Vaccine strategies that are being tested, or have previously been te sted, in humans include subunit, DNA plasmid, and viral vector, and combinations of these various strategies. Some of the results of these trials are promising, and additional research has focused on the development of appropriate chemical and genetic adjuvants as well as methods of vaccine delivery to improve the host immune response. This review summarizes the vaccine strategies that have been tested in both animal models and human clinical trials.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Fast PE, Walker MC: Human trials of experimental AIDS vaccines. AIDS 1993;7:S147-S159.
Mizuochi T, Horino A, Uchida T: Delayed progression of murine AIDS in C57BL.6 mice preimmunized with a highly antigenic 10-mer peptide encoded by the murine AIDS defective virus gag p12 gene. Vaccine 1998;16:2026–2030.
Lanza P, Moss RB, Giermakowska W, Hancock RB, Richieri SP, Theofa G, et al.: Whole-killed gpl 20-depleted HIV-1 antigen in a murine model for prophylactic vaccination. Vaccine 1998;16:727–731.
Wang B, Dang K, Agadjanyan MG, Srikantan V, Li F, Ugen KE, et al.: Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 ata mucosal site. Vaccine 1997;15: 821–825.
Willet BJ, Flynn JN, Hosie MJ: FIV infection of the domestic cat: an animal model for AIDS. Immunol Today 1997;18:182–189.
Hosie M, Osborne R, Yamamoto JK, Neil JC, Jarrett O: Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J Virol 1995;69:1253–1255.
Matteucci D, Pistello M, Mazzetii P, Giamecchini S, Del Mauro D, Zaccaro L, Bandecchi P, Tozzini P, Bendinelli M: Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibo-dies. J Virol 1996;70:617–622.
Matteucci D, Pistello M, Mazzetii P, Giannecchini S, Del Mauro D, Lonetti I, Zaccaro L, Pollera C, Specter S, Bendinelli M: Studies of AIDS vaccination using anexvivo feline immunod eficiency virus model: protection conferred by a fixed cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. J Virol 1997;71:8368–8376.
Matteucci D, Pistello M, Mazzetti P, Giamecchini S, Isola P, Merico A, et al.: AIDS vaccination studies using feline immunodeficiency virus as a model: immunization with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. Vaccine 1999;18:119–130.
Hosie MJ, Flynn JN, Rigby MA, Cannon C, Dunsford T, Mackay NA, et al.: DNA vaccination afford significant protection against feline immunodeficiency virus infection without inducing detect-able antiviral antibodies. J Virol 1998;72:7310–7319.
Sieblink KH, Huisman RC, Huisman W, de Ronde A, Darby IH, Rimmelzwaan GF, Osterhaus AD: Enhancement of feline immunod-eficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 1995;69:3704–3711.
Hosie MJ, Obborne R, Reid G, Neil JC, Jarrett O: Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol 1992;35:191–197.
Richardson J, Moraillon A, Crespeau F, Baud S, Sonigo P, Pancino G: Delayed infection after immunization with a peptide from the transmem brane glycoprotein of the feline immunodeficiency virus. J Virol 1998;72:2406–2415.
Huisman W, Karlas JA, Siebelink HJ, Huisman RC, deRonde A, Francis MJ, Rimmelzwaan GF, Osterhaus AD: Feline immuno deficiency virus subunit vaccines that induce virus neutralising antibodies butno protection against challenge infection. Vaccine 1998;16:181–187.
Leutenegger CM, Hofmann-Lehmann R, Holznagel E, Cuisinier AM, Wolfensberger C, Duquesne V, Cronier J, Allenspach K, Aubert A, Ossen P, Lutz H: Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins. AIDS Res Hum Retroviruses 1998; 14:275–283.
Richardson J, Moraillon A, Baud S, Cuisinier A-M, Sonigo P, Pancino G: Enhancement of feline immuno deficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 1997;71:9640–9649.
Cuisinier AM, Meyer A, Chalrenet B, Verdier AS, Aubert A: Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection. Vaccine 1999;17:415–425.
Tellier MC, Pu R, Pollack D, Vitsky A, Tartaglia J, Paoletti E, Yamamoto JK: Efficacy evaluation of prime-boost protocol: canary-poxvirus-based feline immunode-ficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats. AIDS 1998;12:11–18.
Bibollet-Ruche F, Brengues C, Galat LA, Galat G, Pourrut X, Vidal N, et al.: Genetic diversity of simian immunodeficiency virus from West African green monkeys: evidence of multiple genotypes within populations from the same geographical locale. J Virol 1997;71:307–313.
Edinger AL, Clements JE, Doms RW: Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis. Virol 1999;260:211–221.
Letvin NL, Daniel MD, Sehgal PK, Desrosiers RC, Hunt RD, Waldron LM, MacKay JJ, Schmidt DK, Chalifoux LV, King NW: Induction of AIDS-like diseases in macaque monkeys with T-cell tropic retroviruses STLV-III. Science 1985;230:71–73.
Desrosiers RC: The simian immun-odeficiency viruses. Annu Rev Immunol 1990;8:557–578.
Shafferman A, Lewis MG, McCutchan FE, Benvenieste RE, Jahrling PB, Burke DS, Eddy GA: Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge. Vaccine 1993;11:848–852.
Mooij P, van der Kolk M, Bogers WM, ten Haaft PJ, van der Meide P, Almond N, Stott J, Deschamps M, Labbe D, Momin P, Voss G, von Hoegen P, Bruck C, Heeney JI: A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 1998;12:F15-F22.
Bogers WMJM, Niphuis H, Haaft PT, Laman JD, Koornstra W, Heeney JL: Protection from HIV-1 envelope-hearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques in fected with attenuated SIV: consequences of challenge. AIDS 1995;9:F13-F18.
Clements JE, Montelaro RC, Zinc MC, Amedee AM, Miller S, Trichel AM, Jagerski B, Hauer D, Martin LN, Bohm RP: Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immuno deficiency virus. J Virol 1995;69:2737–2744.
Shibata R, Siemon C, Czajak SC, Desrosiers RC, Martin MA: Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance againsta challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol 1997; 71:8141–8148.
Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996;70:3724–3733.
Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Destrosiers RC: Protection by live, attenuated simian immunodeficiency virus a gainst heterologous challenge. J Virol 1999;73:8356–8363.
Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with adeletion in the nefgene. Science 1992; 258:1938–1941.
Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995;345:1342–1344.
Whatmore AM, Cook N, Hall GA, Sharpe S, Rud EW, Cranage MP: Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 1995;5117–5123.
Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AM, Arthur LO, Johnson RP: Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol 1998;72:1431–1437.
Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, et al.: Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 1996;70:3978–3991.
Boyer JD, Wang B, Ugen KE, Agadjanyan M, Javadian A, Frost P, Dang K, Carrano RA, Ciccarelli R, Coney L, Williams WV, Weiner DB: In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol 1996;25:242–250.
Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, Liljestrom P: Outcome of immunization of cynomologous monkeys with recombinant Sem-like Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 1997; 13:1487–1495.
Benvenieste RE, Kuller L, Roodman ST, Hu S-L, Morton WR: Long-tenn protection of macaques against high-dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins. J Med Primatol 1993;22:74–79.
Igarashi T, Shibata R, Hasebe F, Ami Y, Shinohara K, Komatsu T, et al.: Persistent infection with SIV mac chimeric virus having tat, rev, rpa, env and nef of HIV type 1 in macaque monkeys. AIDS Res Human Retroviruses 1994;10:1021–1029.
Joag SV, Li Z, Foresman L, Stephens EB, Zhao L-J, Adany I, Pinson DM, McClure HM, Narayan O: Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol 1996;70:3189–3197.
Joag SV, Li Z, Wang C, Jia F, Foresman L, Adany I, Pinson DM, Stephens EB, Narayan O: Chimeric SHIV that causes CD4+ T cell loss and AIDS in rhesus macaques. J Med Primatol 1998;27:59–64.
Allan JS, Ray P, Broussard S, Whitehead E, Hubbard G, Butler T, Brasky K, Luciw P, Cheng-Mayer C, Levy JA, Steimer K, Li J, Sodroski J, Garcia-Moll M: Infection of baboons with simian/ human immunodeficiency viruses. J Aquir Immune Defic Syndr Hum Retrovirol 1995;9:429–434.
Klinger JM, Himathongkham S, Legg H, Luciw PA, Barnett SW: Infection of baboons with a simian immunodeficiency virus/HIV-1 chimeric virus corstructed with an HIV-1 Thai subtype E envelope. AIDS 1998;12:849–857.
Novembre FJ, Saucier M, Anderson DC, Klumpp SA, O'Neil SP, Brown CR, Hart CE, Guenthner PC, Swerson RB, McClure HM: Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol 1997;71:4086–4091.
Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wunn FM, Hershberg RD, Cobb EK, Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp1 20 but not gp160. Nature 1990;345:622–625.
Girard M, M.P., Pinter A, Barre-Sinoussi F, Nara P, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczorek M, Gomard E, Gluckman J-C, Fultz PN: Immunization of chimpanzees confers protection against challenge with human immunod-eficiency virus. Proc Natl Acad Sci USA 1991;88:542–546.
Bagarazzi ML, Boyer JD, Ugen KE, Javadian MA, Chattergoon M, Shah A, Bennett M, Ciccarelli R, Carrano R, Coney L, Weiner DB: Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees. Vaccine 1998;16:1836–1841.
Ugen KE, Boyer JD, Wang B, Bagarazzi M, Javadian A, Frost P, et al.: Nucleic acid immunization ofcchimpanzees as a prophylactic/immuno-therapeutic vaccination model for HIV-1: prelude to a clinical trial. Vaccine 1997;15:927–930.
Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Rafaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med 1997;3:526–532.
Boyer JD, Ugen KE, Chattergoon M, Wang B, Shah A, Agadjanyan M, Bagarazzi ML, Javadian A, Carrano R, Coney L, Williams WV, Weiner DB: DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees. J Infect Dis 1997; 176:1501–1509.
Berman PW, Wastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements MI, Byrn RA: Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 1994;8:591–601.
Goebel FD, Mannhalter JW, Belshe RB, Eibl MM, Grob PJ, de Gruttola V, Griffiths PD, Erfle V, Kumschak M, Engl W: Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. AIDS 1999;13:1461–1468.
Ratto-Kim S, Sitz KV, Garner RP, Kim JH, Davis C, Aronson N, Ruiz N, Tencer K, Redfield RR, Birx DL: Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV)eenvelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. J Infect Dis 1999; 179:337–344.
Sitz KV, Ratto-Kim S, Hodgkins AS, Robb ML, Birx DL: Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. J Infect Dis 1999;179:817–824.
Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, et al.: HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 1999;13:2003–2012.
Lambert JS, McNamara J, Katz SL, Fenton T, Kang M, VanCott TC, Livingston R, Hawkins E, Moye J, Jr., Borkowsky W, Johnson D, Yogev R, Duliege AM, Francis D, Gershon A, Wara D, Martin N, Levin M, McSherry G, Smith G: Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (AC TG-218). J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:451–461.
Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, Wara DW, Anderson EL, Keefer MC, Jackson S, Wagner LJ, Francis DP, Fast PE, McNamara J: Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J Infect Dis 1999;180:1080–1088.
Moss RB, Wallace MR, Giermakowska WK, Webb E, Savary J, Chamberlin-Brandt C, Theofan G, Musil R, Richieri SP, Jensen FC, Carlo DJ: Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. J Infect Dis 1999;180:641–648.
Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price LD, Cox JH, Jarosinski P, Walsek CM, Browers P, Venzon DJ, Xu J, Pizzo PA, Moss RB, Robb ML, Wood LV: Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. J Infect Dis 1999;180:626–640.
Benson EM, Clarkson J, Law M, Marshall P, Kelleher AD, Smith DE, Paton G, Stewart GJ, Cooper DA, French RA: Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res Hum Retroviruses 1999;15:105–113.
Patterson BK, Carlo DJ, Kaplan MH, Marceki M, Pawha S, Moss RB: Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen. AIDS 1999; 13:1607–1611.
Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB: HIV-IMN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-IMN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1999;15:115–132.
Kang CY, Luo L, Wainberg MA, Li Y: Development of HIV/AIDS vaccine using chimeric gag-envirus-like particles. Biol Chem 1999;380:353–364.
Cox JH, Garner RP, Redfield RR, Aronson NE, Davis C, Ruiz N, Birx DL: Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving Vax Syn, a recombinant gp160 envelope vaccine. AIDS Res Hum Retroviruses 1999;15:847–854.
Beddows S, Lister S, Cheingsong R, Bruck C, Weber J: Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J Virol 1999;73:1740–1745.
Gorse GJ, Patel GB, Mandava M, Berman PW, Belshe RB: MN and II1B recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1999;15:921–930.
Takahashi A, Ogasawara K, Matsuki N, Fujinaga K, Nakaya T, Ikuta K, Auwanit W, Honda M, Fukui Y, Sasazuki T, Iwabuchi K, Onoe K: Development of peptide vaccines inducing production of neutralizing antibodies against HIV-1 viruses in HLA-DQ6 mice. Vaccine 1998;16:1537–1543.
Barbouche R, Fenouillet E, Papandreou MJ, Kieny MP, Sabatier JM: Properties of HIV envelope expressed in the presence of SPC3, anEnv-derived peptide drug under phase II clinical trials. J Pept Res 1998;52:283–288.
Liang X, Munshi S, Shendure J, Mark G, 3rd, Davies ME, Freed DC, Montefiori DC, Shiver JW: Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 1999;17:2862–2872.
Sarin PS, Talmadge JE, Heseltine P, Murcar N, Gendelman HE, Coleman R, Kelsev L, Beckner S, Winship D, Kahn J: Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Vaccine 1999;17:64–71.
Gringeri A, Santagostino E, Muca-Perja M, Mannucci PM, Zagury JF, Bizzini B, Lachgar A, Carcagno M, Rappaport J, Criscuolo M, Blatner W, Burny A, Gallo RC, Zagury D: Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol 1998;1:293–298.
Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Golleti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo ML, Betti M, Borsetti A, Belli R, Akerblom L, Corrias F, Butto S, Heeney J, Verani P, Titti F, Ensoli B: Control of SHIV-89.6P-infection of cynomologus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999;5:643–650.
Bruce CB, Akrigg A, Sharpe SA, Hanke T, Wilkinson GW, Cranage MP: Replication-deficient recombinant adenoviruses expressing the human immuno deficiency virus Env antigen can induce both humoral and CTL immune responses in mice. J Gen Virol 1999;80:2621–2628.
Caley IJ, Betts MR, Davis NL, Swanstrom R, Frelinger JA, Johnston RE: Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 1999;17:3124–3135.
Smith AD, Geisler SC, Chen AA, Resnick DA, Roy BM, Lewi PJ, Arnold E, Arnold GF: Human rhinovirus type 14: human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1. J Virol 1998;72:651–659.
Salmon-Ceron D, Excler JL, Finkielsztein L, Autran B, Gluckman JC, Sicard D, et al.: Safety and immunogenicity of a live recombinant canary pox virus expressing HIV type 1 gp120 MN MN tm/gap/protese LA1 (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'A gence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses 1999;15:633–645.
Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montifiore D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler JL, Duliege AM, Tartaglia J: Acanary-pox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180:290–298.
Fomsgaard A: HIV-1 DNA vaccines. Immunol Lett 1999;65:127–131.
Montelaro RC, Cole KS, Hammond SA: Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res Hum Retroviruses 1998;14Suppl 3:S255-S259.
Sattentau QJ, Moulard M, Brivet B, Botto F, Guillemot JC, Mondor I, Poignard P, Ugolini S: Antibody neutralization of HIV-1 and the potential for vaccine design. Immunol Lett 1999;66:143–149.
Ugen KE, Rushing GD, Vidal C, Kim J, Javadian A, Boyer J, Weiner DB: Beta chemokine levels in non-human primates modulated in vivo by HIV-1 DNA vaccines. Procedings of the 12th World AIDS Conference. 5:55–59, 1998.
Hanke T, McMichael A: Preclinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol Lett 1999;66:177–181.
Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, Wahren B: Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351:1320–1325.
Haynes BF, Pantaleo G, Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271:324–328.
Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, Whittle H: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women [published erratum appearns in Nat Med 1995 Jun;1(6):598]. Nat Med 1995;1:59–64.
Sasaki S, Tsuji T, Asakura Y, Fukushima J, Okuda K: The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Anticancer Res 1998; 18:3907–3915.
Kim JJ, Simbiri KA, Sin JI, Dang K, Oh J, Dentchev T, Lee D, Nottingham LK, Chalian AA, McCallus D, Ciccarelli R, Agadjanyan MG, Weiner DB: Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res 1999; 19:77–84.
Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, Weiner DB: In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997;158:816–826.
Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, Frost JD, Krivulka GR, Lifton MA, Crabbs CL, Heidecker G, Perry HC, Davies ME, Xie H, Nickerson CE, Steenbeke TD, Lord CI, Montefiore DC, Strom TB, Shiver JW, Lewis MG, Letvin NL: Augmentation of immune responses to HIV-1 and simian immunodeficiency virus: DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. PNAS 2000;97:4192–4197.
Xin KQ, Hamajima K, Sasaki S, Tsuji T, Watabe S, Okada E, Okuda K: IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 1999;17:858–866.
Lee AH, Suh YS, Sung YC: DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses. Vaccine 1999; 17:473–479.
Boyer JD, Kim J, Ugen K, Cohen AD, Ahn L, Schumann K, Lacy K, Bagarazzi ML, Javadian A, Ciccarelli RB, Ginsberg RS, MacGregor RB, Weiner DB: HIV-1 DNA vaccines and chemokines. Vaccine 1999;17Suppl 2:S53-S64.
Ihata A, Watabe S, Sasaki S, Shirai A, Fukushima J, Hamajima K, Inoue J, Okuda K: Immunomodulatory effect of a plasmid expressing C D40 ligand on DNA vaccination against human immunodeficiency virus type-1. Immunology 1999;98:436–442.
Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, Ciccarelli R, Chattergoon MA, Dang K, Mahalingam S, Chalian AA, Agadjanyan MG, Boyer JD, Wang B, Weiner DB: Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997;15:641–646.
Kim JJ, Nottingham LK, Wilson DM, Bagarazzi ML, Tsai A, Morrison LD, Javadian A, Chalian AA, Agadjanyan MG, Weiner DB: Engineering DNA vaccines viacodelivery of co-stimulatory molecule genes. Vaccine 1998;16:1828–1835.
Santra S, Barouch DH, Sharpe AH, Letvin NL: B7 co-stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination. Eur J Immunol 2000; 30:2650–2659.
Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB: Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccineadjuvants. J Virol 2000;74:3427–3429.
Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486–492.
Boyer JD, Cohen AD, Ugen KE, Edgeworth RL, Bennett M, Shah A, Schumann K, Nath B, Javadian A, Bagarazzi ML, Kim J, Weiner DB: Therapeutic Immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and IL-12 expressing plasmids. AIDS 2000; In Press.
Vinner L, Nielsen HV, Bryder K, Corhet S, Nielsen C, Fomsgaard A: Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vaccine 1999;17:2166–2175.
Nappi F, Schneider R, Zolotukhin A, Smulevitch S, Michalowski D, Bear J, Felber BK, Pavlakis GN: Identification of a novel posttranscriptional regulatory element by using a rev- and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap. J. Virol 2001;75:4558–4569.
Collings A, Pitkanen J, Strengell M, Tahtinen M, Lagerstedt A, Hakkarainen K, Ovod V, Sutter G, Ustav M, Ustav E, Mannik A, Ranki A, Peterson P, Krohn K: Humoral and cellular immune responses to HIV-1 nef in mice DNA-immunised with non-replicating or self-replicating expression vectors. Vaccine 1999;18:460–467.
Caver TE, Lockey TD, Srinivas RV, Webster RG, Hurwitz JL: A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 1999;17:1567–1572.
Caselli E, Betti M, Grossi MP, Balboni PG, Rossi C, Boarini C, Cafaro A, Barbanti-Brodano G, Ensoli B, Caputo A: DNA immunization with HIV-1 tat mutated in the transactivation domain induces humoral and cellular immune responses against wild-type Tat. J Immunol 1999;162:5631–5638.
Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997; 3:526–532.
Bagarazzi ML, Boyer JD, Javadian MA, Chattergoon MA, Shah AR, Cohen AD, Bennett MK, Ciccarelli RB, Ugen KE, Weiner DB: Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees. J Infect Dis 1999; 180:1351–1355.
Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, Robinson HL: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69–74.
Ugen KE, Nyland SB, Boyer JD, Vidal C, Lera L, Rasheid S, Chattergoon M, Bagarazzi ML, Ciccarelli R, Higgins T, Baine Y, Ginsberg R, Macgregor RR, Weiner DB: DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998;16:1818–1821.
MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB: First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998;178:92–100.
Calarota SA, Leandersson AC, Bratt G, Hinkula J, Klinman DM, Weinhold KJ, Sandstrom E, Wahren B: Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral tratment. J Immunol 1999;163:2330–2338.
Sasaki S, Tsuji T, Hamajima K, Fukushima J, Ishii N, Kaneko T, Xin KQ, Mohri H, Aoki I, Okubo T, Nishioka K, Okuda K: Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vacciration agaist human immunodeficiency virus type 1. Infect Immun 1997;65:3520–3528.
Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, Kawamoto S, Mohri H, Kensil CR, Okuda K: Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol 1998;72:4931–4939.
Sasaki S, Fukushima J, Hamajima K, Ishii N, Tsuji T, Xin KQ, Mohri H, Okuda K: Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1 [published erratum appears in Clin Exp Immunol 1998 May; 112(2):354]. Clin Exp Immunol 1998;111:30–35.
Ishii N, Fukushima J, Kaneko T, Okada E, Tani K, Tanaka SI, Hamajima K, Xin KQ, Kawamoto S, Koff W, Nishioka K, Yasuda T, Okuda K: Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1997;13:1421–1428.
Toda S, Ishii N, Okada E, Kusakabe KI, Arai H, Hamajima K, Gorai I, Nishioka K, Okuda K: HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannancoated liposomes and inhibited by anti-interferon-gamma antibody. Immunology 1997;92:111–117.
Singh M, Briones M, Ott G, O'Hagan D: Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000;97:811–816.
Arthur LO, Besse JJ, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, Benveniste RE: Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 1995;69:3117–3124.
Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G: Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:301–309.
Belshe RH, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ: Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gpl 20 SF-2 recombinant vaccines in unifected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998;12:2407–2415.
Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler JL, Tartaglia J, Paoletti E, Group NAVE: Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gpl20, HIV-1SF2 recombinant gpl20, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:1230–1246.
Montefiori DC, Evans TG: Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res Hum Retroviruses 1999;15:689–698.
Goepfert P, Mulligan M, Corey L, Graham B, Evans T, K. W., Stablein D, Ginsberg R. AV EG031: phase 1 evaluation of a gag-pol facilitated DNA vaccine for HIV-1. Int Conf AIDS. 12:635 (abstract #33216), 1998.
Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW: Advacing AIDSVAX to phase 3. Safety, immunogencity, and plans for phase 3. A01DS Res Hum Retroviruses 1998;14:S325-S331.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Edgeworth, R.L., Juan, H.S., Rosenzweig, J.A. et al. Vaccine development against HIV-1. Immunol Res 25, 53–74 (2002). https://doi.org/10.1385/IR:25:1:53
Issue Date:
DOI: https://doi.org/10.1385/IR:25:1:53